How GLP-1 drugs (Ozempic, Wegovy) work on appetite — and the melanocortin connection

The defining drugs of the moment — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) — are GLP-1 receptor agonists, and the question everyone asks is how they make people eat less. The short answer is that they work on the brain. The more interesting answer, for this site, is that the circuit they act on is the one melanocortin biology has described all along.

The body's appetite thermostat

Hunger and fullness are set in the hypothalamus by a small, well-mapped circuit. The fat-derived hormone leptin activates POMC neurons in the arcuate nucleus, which release α-MSH onto MC4R — and MC4R activation is the body's core "stop eating" signal. Pulling the other way are AgRP neurons, which drive hunger and block MC4R. Appetite is the balance between them, which is why losing either POMC or MC4R causes severe obesity, and why MC4R mutations are the commonest single-gene cause of it.^[1]The overview pillar covers this circuit in full.

Where GLP-1 plugs in

GLP-1 receptor agonists engage this same circuit. In the arcuate nucleus they activate the satiety-promoting POMC neurons and quiet the hunger-promoting AgRP/NPY neurons — tilting the balance toward fullness and feeding directly into the melanocortin pathway downstream.^[2] In other words, part of how a GLP-1 drug suppresses appetite is by raising melanocortin tone and handing the signal to MC4R, the same receptor the obesity drug setmelanotide targets directly.

But the melanocortin pathway isn't the whole story

Here is where an honest account has to slow down. If GLP-1 drugs workedonly through MC4R, people with disabling MC4R mutations shouldn't respond to them — yet they do. In a key study, patients with obesity caused by MC4R mutations still lost weight on a GLP-1 receptor agonist, which means the melanocortin pathway is not an obligatory gateway for GLP-1's effect.^[3] The drug appears to have parallel routes — through other hypothalamic and brainstem neurons — that can bypass MC4R. So the accurate picture is that GLP-1 strongly engages the melanocortin system without being wholly dependent on it. Where the science is still being worked out, this page says so.

One hub, many drugs

Step back and a pattern appears: leptin, the melanocortin peptides, setmelanotide, and now GLP-1 drugs all converge on or around the same hypothalamic appetite circuit. That convergence is why MC4R agonists such as setmelanotide remain the right tool for specific genetic defects that sitinside the melanocortin pathway, while GLP-1 drugs act more broadly — and why combining the two is an active area of interest — a Phase 2 pairing a low-dose MC4R agonist with a GLP-1 drug even curbed weight regain after the GLP-1 was stopped.^[1][4] Thesetmelanotide explainer covers the approved MC4R drug in depth, and the therapeutics section covers the melanocortin agents directly.

The bottom line

The GLP-1 era did not replace the melanocortin story — it validated it. The hypothalamic appetite thermostat that melanocortin research spent decades mapping turned out to be exactly the dial the world's best-selling weight drugs turn. Understanding MC4R is, increasingly, how you understand modern obesity medicine.

This page explains mechanism for education only — it is not medical advice or guidance on using any medication. See theeditorial standards.

Common questions

Does Ozempic work on the brain?+

Yes. Although GLP-1 is a gut hormone, GLP-1 drugs like semaglutide reduce appetite largely by acting on hunger-regulating circuits in the hypothalamus and brainstem, not only on the gut and pancreas.

Do GLP-1 drugs work through the melanocortin system?+

Partly. GLP-1 receptor agonists activate POMC neurons and quiet AgRP/NPY neurons, which feeds the melanocortin (MC4R) satiety pathway. But they do not fully depend on it: people with MC4R mutations still lose weight on a GLP-1 drug, so parallel circuits are also involved.

Why do GLP-1 drugs reduce appetite?+

They mimic the gut hormone GLP-1, signalling fullness to the brain’s appetite centres and slowing gastric emptying, which together lower how much you eat.

Is MC4R the same target as Ozempic?+

No. Semaglutide targets the GLP-1 receptor, not MC4R. But the two pathways meet — GLP-1 signalling feeds into the MC4R appetite circuit — which is why they are discussed together and explored in combination.

References

1. 1.Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 27(7):736–49. 2006. link ↗
2. 2.Dong Y, et al. Time- and metabolic-state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol Metab. 54:101352. 2021. link ↗
3. 3.Iepsen EW, et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab. 28(1):23–32. 2018. link ↗
4. 4.StatPearls. Setmelanotide. NCBI Bookshelf (NBK589641). 2024. link ↗